Antisense modulation of PTP1B expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsLex M. Cowsert, Jacqueline Wyatt, Brett P. Monia, Madeline M. Butler, Robert McKay
Life of this patent
Estimating the term…
Abstract
Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
Claims72
A method of decreasing blood glucose levels in an animal comprising administering to said animal an effective amount of a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.
A method of preventing or delaying the onset of an increase in blood glucose or plasma insulin levels in an animal comprising administering to said animal an effective amount of a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.
A method of decreasing plasma insulin levels in an animal comprising administering to said animal an effective amount of a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.
A method of treating or delaying the onset of Type 2 diabetes in an animal comprising administering to said animal an effective amount of a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.
Dependencies are inferred from the claim text.